Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly R&D personnel changes

Executive Summary

Leader of Lilly's Zyprexa product team and clinical research fellow Alan Breier, MD, assumes Chief Medical Officer and VP-Medical position; Breier replaces Michael McDonald, MD, who is leaving Lilly. VP-Clinical Research and U.S. Regulatory Affairs and Policy Tim Franson, MD, replaces Michael Clayman, MD, as VP-Global Regulatory Affairs; Clayman moves into the new position of VP-Lilly Research Laboratories. Breier and Franson report to Steven Paul, MD, recently appointed R&D president (1"The Pink Sheet" May 19, 2003, p. 16)...

You may also be interested in...

Lilly Picks Paul’s Brain: CNS Researcher To Succeed R&D Head Watanabe

Lilly R&D president-elect Steven Paul, MD, will bring an extensive background in central nervous system discovery and research to Lilly's top research position

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts